BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rheonix, Inc. Executive to Address Costs and Benefits of Genetic Testing


6/4/2013 11:28:20 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ITHACA, N.Y. – While advancements in genetic testing have enabled rapid, more sensitive and specific methods to aid in the diagnoses and appropriate treatment of diseases including cancer, hemophilia, sickle cell anemia and cystic fibrosis, such advancements can come at a cost to both health care providers and patients. Molecular diagnostics executive Richard Montagna, Ph.D., vice president for scientific affairs for Rheonix Inc., an Ithaca-based developer of an automated molecular testing platform, will present ideas at a national conference about how medical laboratories can select, develop and perform diagnostic tests that make sense from a clinical and cost standpoint.

“If laboratories are able to make better economic decisions, then hopefully the costs of genetic testing will stabilize resulting in significant therapeutic benefits for more patients. This will not only help limit cost increases for patients, but also yield better clinical outcomes,” Montagna said.

Montagna, based at the Grand Island, N.Y., location of Rheonix, is a featured presenter at the upcoming MDx Next Conference in Las Vegas, Nev. MDx Next is sponsored by G2 Intelligence, an industry analysis firm, and provides independent laboratories, hospital laboratories, in vitro diagnostics companies and pathology practices from across the United States with business strategies to navigate the current industry landscape.

His talk, “Providing Cost-Effective Molecular Diagnostics: How to Overcome the Challenges,” will outline the factors laboratories should consider before performing any tests. He will also help explain the challenges associated with providing diagnostics for personalized medicine and companion diagnostics in a manner that meets the needs of laboratories, patients, physicians, payers and manufacturers.

Montagna has more than 30 years of leadership experience and has managed the commercialization of more than 40 biotechnology products. He has published 40 scientific papers, holds a number of patents in the biosensor area and is an adjunct professor in the department of biological and environmental engineering at Cornell University.

MDx Next is June 12-14 at the Westin Las Vegas Hotel Casino & Spa. Montagna is scheduled to present at 9-9:45 a.m. on June 13.

About Rheonix: Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx™ platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES